Andrea Lobo,  —

Physical exercise may reduce the risk of developing Parkinson’s disease, as well as effectively control patients’ symptoms, according to a review analysis by researchers in Europe. Moreover, some studies suggest that exercise might be a potential disease-modifying treatment, working to slow disease progression and stabilizing, or even reducing, the…

The European Inventor Award 2024 has named as finalists a French husband-and-wife team of scientists who developed a dosing pump that allows for direct delivery of dopamine to the brain in people with Parkinson’s disease. The use of dopamine is expected to help reduce symptoms and so-called off…

Serina Therapeutics has partnered with Enable Injections to advance SER-252 (POZ-apomorphine), Serina’s lead treatment candidate for advanced Parkinson’s disease, in combination with the enFuse wearable delivery system. EnFuse is designed to allow patients to self-administer SER-252 subcutaneously (under the skin) in a faster, simpler, and more…

An oral spray was safe and efficient at delivering apomorphine to people with Parkinson’s disease, a study found. A subcutaneous injection formulation of apomorphine, sold as Apokyn, is approved in the U.S. to treat off episodes — periods in which symptoms return between doses of levodopa treatment — in…

A region in the alpha-synuclein protein has been identified as a possible target for inhibiting the conversion of oligomers — early aggregates, or clumps, of the protein — into toxic fibrils, a hallmark of Parkinson’s disease, according to a recent study. Mutations in this region are also associated with…

Aspen Neuroscience has been awarded an $8 million grant to advance the clinical development of ANPD001, its investigational stem cell therapy that’s designed to replace dopamine-producing nerve cells lost in Parkinson’s disease. The grant, funded by the California Institute for Regenerative Medicine (CIRM), will support the ongoing Phase…

Enhancing mechanisms associated with the degradation of misfolded proteins at the proteasome, that is, cellular structures where these proteins are degraded, may be a new therapeutic target for neurodegenerative diseases, including Parkinson’s disease. That’s according to a new study in fruit flies, where researchers found that the ZIP7 protein,…

The first 25 patients have been enrolled in a Phase 3 trial that’s testing the light-based, at-home therapy device called Celeste for treating Parkinson’s disease, its developer PhotoPharmics has announced. The “Celeste Light for PD Trial” is evaluating the device’s safety and effectiveness at easing both motor…

A newly developed molecule showed an ability in lab studies to activate antioxidant responses in brain cells by altering how two proteins, believed to be involved in the development of Parkinson’s disease and other neurodegenerative conditions, interact. The small molecule, known as a protein-like polymer, is designed to bind to…

Topline efficacy data from a Phase 3 clinical trial evaluating the oral therapy buntanetap for early-stage Parkinson’s disease is now expected in June, Annovis Bio, the therapy’s developer, has disclosed. While Annovis originally planned to share its early findings at the beginning of this year, the company faced…